InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: jondoeuk post# 157

Monday, 08/29/2022 2:31:32 PM

Monday, August 29, 2022 2:31:32 PM

Post# of 386
ONKT104 is an anti-CLL-1 (+/- a second CAR) CAR-NK cell product with CISH knockout, and possibly a DR4-specific TRAIL variant https://www.sciencedirect.com/science/article/pii/S1465324922007393

Finally, ONKT103 is an anti-MUC-1 CAR-NK cell product with CISH knockout, and possibly a DR5-specific TRAIL variant, as well as knockout of inhibitory receptors.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News